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SUMMARY
Botulinum toxin (BTX) is a neurotoxic protein produced by Clostridium botulinum, an anaerobic bacterium. BTX therapy is a safe and 
effective treatment when used for functional silencing of the salivary glands in disorders such as sialoceles and salivary fistulae that may 
have a post-traumatic or post-operative origin. BTX injections can be considered in sialoceles and salivary fistulae after the failure of or 
together with conservative treatments (e.g. antibiotics, pressure dressings, or serial aspirations). BTX treatment has a promising role in 
chronic sialadenitis. BTX therapy is highly successful in the treatment of gustatory sweating (Frey’s syndrome), and could be considered 
the gold standard treatment for this neurological disorder.
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RIASSUNTO
La tossina botulinica è una neurotossina prodotta dal batterio anaerobio Clostridium botulinum. L’iniezione di tossina botulinica è un 
trattamento sicuro ed efficace quando viene usata per inibire la funzione delle ghiandole salivari in patologie come gli sialoceli o le fistole 
salivari di origine post-traumatica o iatrogena. Negli scialoceli e fistole salivari, il trattamento con tossina botulinica può essere preso in 
considerazione anche dopo il fallimento o in aggiunta ai trattamenti conservativi non chirurgici. La terapia con tossina botulinica si sta 
dimostrando promettente anche nel trattamento della scialoadenite cronica. La tossina botulinica ha un elevato tasso di risoluzione nella 
Sindrome di Frey ed è considerata il gold standard nel trattamento di questo disturbo neurologico.
PAROLE CHIAVE: Tossina botulinica • Sialocele • Fistola salivare • Scialoadenite cronica • Sindrome di Frey
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Introduction
Botulinum toxin (BTX) is produced by Clostridium botuli-
num, an anaerobic bacterium. The bacterium produces sev-
en serological types of toxins (A, B, C1, D, E, F and G) as a 
complex mixture of neurotoxic polypeptides and nontoxic 
protein components 1. BTX type A (BTX-A) and B (BTX-
B) are commercialised and available for medical use 2.
The application by injection of BTX on salivary glands 
was first proposed in 1997 as treatment for sialorrhoea 3, 
and in 1999 we proposed BTX injection in parotid 
sialocele 4. The toxin is able to depress secretory activ-
ity of the salivary glands reducing saliva production. At 
neuromuscular junctions, BTX inhibits presynaptic ace-
tylcholine release by interfering with the neuroexocyto-
sis process, and causes flaccid muscle paralysis 5. With 
the same mechanism, BTX on salivary glands acts on the 
cholinergic nerve terminals (parasympathetic nerve termi-
nals), and produces a local chemical blocking and loss of 
neuronal activity 3. 
The localised cholinergic block achieved by BTX injec-
tion inhibits salivary flow and allows healing of salivary 
disorders. BTX therapy has been effectively used in 
various salivary disorders, such as salivary fistulae after 
sialadenectomy 6 7, post-traumatic and iatrogenic sali-
vary sialoceles 8-10 and chronic sialadenitis 11. BTX has 
also been successfully used to treat auriculo-temporal (or 
Frey’s) syndrome 12 13, as it reduced the skin area affected 
by gustatory sweating by inhibiting the sweat glands ab-
normally re-innervated after parotidectomy by the cholin-
ergic pathway 14.
In the present paper, we critically review the current indi-
cations and treatment modalities for BTX therapy in sali-
vary gland disorders (and in Frey’s syndrome).
Salivary fistula and sialoceles
Parotid fistula is a chronic wound of the gland or its 
duct through which saliva is discharged 15. Sialocele is a 
collection or retention of saliva in the gland soft tissue. 
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Salivary fistulae and sialoceles may occur after penetrat-
ing injuries of the salivary glands (in peacetime practice 
mainly due to shattered glass in road accidents), or as a 
complication of partial parotidectomy 16. Parotid fistula 
has also been reported after rhytidectomy, mastoidecto-
my, dental extraction, temporomandibular joint surgery 
and mandibular osteotomy 7; submandibular sialocele can 
be due to sialoadenectomy 9. According to our experience 
with post-operative parotid fistula 7, after an initial (4 to 
8 postoperative days) swelling beneath the wound in the 
area overlying the parotid, an efflux of clear fluid from 
the wound occurs. The flow through the fistula increases 
during meals, particularly during mastication. In dubious 
cases, analysis of the fluid can confirm parotid secretion 
because of to its high amylase content 7.
Sialocele and salivary fistula, especially when post-trau-
matic, can be managed by conservative non-operative 
treatment that includes antibiotics, pressure dressings and 
serial aspirations 17. With conventional management tech-
niques, it is very difficult to abolish salivary flow and re-
solving these salivary disorders may take time, involving 
a lengthy hospital stay and considerable discomfort. Wax 
and Tarshis 15 successfully treated 14 cases of post-parot-
idectomy fistula with pressure dressing; 9 cases healed af-
ter 2 to 9 days, whereas the others needed 10 to 36 days of 
treatment (average period 21 days). Systemic anticholin-
ergic drugs (which may temporarily lead to a reduction in 
salivary secretion) may be associated, but they often cause 
distressing side effects 18, including dryness of the mouth, 
blurred vision, urine retention, photophobia, tachycar-
dia, palpitation and anhydrosis with heat intolerance  19. 
In the treatment of parotid fistulae, the several therapies 
that have been described (i.e. pressure dressing, systemic 
anticholinergic drugs, suction drain insertion, tympanic 
neurectomy with or without chorda tympani section, sur-
gery and use of 2-octyl cyanoacrylate in persistent cases) 
frequently show disappointing outcomes 20 21. Considering 
parotidectomy completion, post-operative fibrosis makes 
it difficult to dissect the tissue plane with frequent perma-
nent facial paralysis 22.
In order to avoid surgical management, BTX therapy 
could be used to obtain a temporary functional silencing 
of the salivary glands and to allow sialocele and fistula 
healing 11. Lim and Choi 23 successfully treated a parotid 
salivary fistula with one BTX injection as the only pri-
mary therapy without pressure dressing. BTX treatment 
has proven successful for the treatment of salivary fis-
tula and sialocele, either post-traumatic or post-oper-
ative  6-11  16  17  19  23-25. Capaccio et al. 24 reported the treat-
ment by BTX of 3 patients with salivary fistula and 5 
with sialocele: complete clinical recovery was observed 
in all but one patients. Furthermore, the authors focused 
on the need for a combination of traditional percutane-
ous aspiration of extravasated fluid and BTX injection 
to avoid invasive sialadenectomy 24, as also proposed by 
other authors 16. Laskawi and colleagues 25 reviewed their 
experience with BTX treatment in 12 post-parotidectomy 
salivary fistulae; they reported 90% of successful fistula 
closures if early treatment (within 6 weeks after develop-
ment of the fistula) was performed. Considering the re-
sults of our clinical experience with post-operative fistula 
(16 cases to date), we suggested early BTX treatment to 
avoid the epithelial coating of the fistulous tract 7. 
Chronic sialadenitis
BTX was used for the first time for the treatment of 2 
cases of chronic sialadenitis by Ellies et al. 11. They sug-
gested that a temporary silencing of the gland might pro-
mote the regeneration of the gland tissue, avoiding gland 
excision, which is often necessary in recurrent chronic 
sialadenitis 11. Treatment with BTX in chronic sialadenitis 
due to Stensen’s duct strictures was effective in reduction 
of recurrent parotitis 24 and gland swelling 26. Traditional 
treatment options for parotid duct strictures included con-
servative methods, such as antibiotics, analgesics, or self-
massage of the gland 27. As second-line therapy, minimal-
ly invasive sialendoscopic dilation of the duct has to be 
considered 26, using BTX therapy only in persistent cases 
after sialendoscopy. Recently, BTX was also used in two 
cases of Sjögren’s syndrome-associated recurrent paroti-
tis with good outcomes 28 29. For these salivary gland dis-
orders, it appears that BTX injections at regular intervals 
are needed (every 3-4 months), as temporary silencing of 
the glands would not be sufficient 29.
Frey’s syndrome
A quite frequent and well-described complication of pa-
rotidectomy is gustatory sweating or Frey’s syndrome. 
The pathogenesis is based on the aberrant regeneration 
of sectioned parasympathetic secretomotor fibres of the 
auriculo-temporal nerve with inappropriate innervation of 
the cutaneous facial sweat glands that are normally in-
nervated by sympathetic cholinergic fibres 30. As a con-
sequence, Frey’s syndrome is a disorder characterised by 
unilateral sweating and flushing of the facial skin in the 
area of the parotid gland occurring during meals that usu-
ally becomes evident 1-12 months after surgery 30. Ac-
cording to a survey of post-parotidectomy patients, the 
incidence of Frey’s syndrome was 23%, while it was ob-
served in 62% of cases using Minor’s starch-iodine test 31. 
The Minor test is usually used to identify and mark the 
margins of the area involved by gustatory sweating.
Systemic or topical application of various anticholiner-
gic agents (scopolamine, glycopyrrolate, diphemnanil-
methylsulfate) and surgical treatment (including cervical 
sympathectomy, tympanic neurectomy, sternocleidomas-
toid transfer and dermis-fat grafts and the use of various 
materials, as interpositional barriers) have been proven 
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unsuccessful for Frey’s syndrome 32. On the contrary, good 
results have been obtained by local injection of BTX, as 
the neurotoxin inhibits pre-synaptic acetylcholine release, 
reducing eccrine glands secretions and sweating 32. The 
gustatory sweating usually ceased in the treated area with-
in 48-72 hours after the first BTX injection. 
Treatment with BTX in Frey’s syndrome reduces hy-
perhidrosis and facial gustatory flushing, as described 
by Tugnoli et colleagues 33. A recent systematic meta-
analysis by Xie et al. 34 on the effectiveness of BTX-A 
therapy for Frey’s syndrome reported an effective rate of 
more than 98% 34. In 2001, Tugnoli et al. described the 
treatment of Frey’s syndrome with BTX type F (BTX-F) 
in a patient with immuno-resistance to BTX-A 35. BTX 
was also effective in diabetic autonomic gustatory sweat-
ing; in 2002 Restivo et al. treated with success 14 diabetic 
subjects with gustatory sweating 36. We can currently state 
that BTX injections is the gold standard treatment for 
Frey’s syndrome.
Discussion
BTX has proven to be efficient in the treatment of sali-
vary disorders such as sialocele 24 and salivary fistula 25. 
Furthermore, BTX may have an emergent role in the 
treatment of chronic sialadenitis 29. BTX injections are ef-
fective in most of the patients with Frey’s syndrome  34. 
The majority of authors used BTX-A for salivary gland 
disorders 24 25 37 and gustatory sweating 31, even if the use 
of BTX-B 16 and BTX-F 35 has been described in salivary 
gland disease.
The dose of BTX-A injected in the parotid gland, to treat 
sialoceles and salivary fistulae, varied in different studies 
from 10 to 60 mouse units (MU) 7 11 24. Capaccio et al. 24 
used 25 to 60 MU per treatment fractionated into 4 doses 
as the parotid was divided into anterior, posterior, up-
per, and lower quadrants. In their case series, the authors 
treated drooling, salivary fistulae, sialoceles and recurrent 
parotitis, without giving precise indications regarding the 
doses used in the different entities 24. Treating post-parot-
idectomy salivary fistulae, we had complete healing of all 
the fistulae using a single lower dose (10 to 20 MU) frac-
tionated in 3 doses (two for the superior and one for the 
inferior lobe) 7. For post-parotidectomy fistulae, Laskawi 
et al. 25 reported a total dose of BTX-A between 10 and 
40 U, depending on the size of the remaining glandular 
compartment. The injections were performed into the 
gland at two to three sites; three patients got two injec-
tions because of persistent leakage of saliva after the first 
injection 25. In Frey’s syndrome, the area identified by the 
Minor test is divided into 1 or 1.5 cm squares, and 2 MU 
of BTX-A are injected, subcutaneously, into each square 
to achieve a diffuse, homogeneous effect 24 32.
In cases of parotid salivary fistulae, we injected BTX un-
der electromyographic (EMG) control on an ambulatory 
basis with little discomfort. We used a tuberculin syringe 
with a 27-gauge monopolar Teflon-coated hollow EMG 
recording needle connected to an EMG recorder for the 
injection. To prevent the masseter and pterygoideus mus-
cles from improperly weakening with the needle in place, 
patients were instructed to open and close their mouths, 
and the EMG signals were observed 7 38. Other authors 
used ultrasonographic-assisted intraparenchymal infiltra-
tion 11 24 25. Both techniques were effective and with few 
reported mild complications, such as transitory paresis of 
the lower branch of the facial nerve 11 and change of saliva 
thickness 38. Injections for Frey’s syndrome should also be 
considered safe as only transient paresis of the orbicularis 
oris, in very few cases, has been reported 32.
In view of the effectiveness and the absence of significant 
side effects in treatment of parotid fistula and sialocele, 
BTX therapy may be indicated as a precautionary treatment 
both in partial parotidectomies and in the management of 
deep facial wounds that affect the parotid gland  7. Recent-
ly, to avoid the onset of salivary complications, the use of 
BTX has been proposed after facial transplantation 39.
Conclusions
BTX injection is a safe and effective treatment when used 
for functional silencing of the salivary glands in disorders 
such as sialoceles and salivary fistulae, and also shows 
a promising role in chronic sialadenitis therapy. BTX 
therapy is highly successful in the treatment of gustatory 
sweating (Frey’s syndrome), and could be considered the 
gold standard treatment for this post-parotidectomy com-
plication.
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